PhD Scientific Days 2023

Translational Medicine - Posters P

Risk Factors of Microscopic Colitis: a Systematic Review and Meta-analysis

Előadó neve

Dr. Rancz, Anett

Neptun code

Q86IE0

Előadó munkahelye

Centre for Translational Medicine, Semmelweis University

Előadó telefonszáma

+36300965760

Előadó e-mail címe

rancz.anett@gmail.com

Az előadás címe

Risk Factors of Microscopic Colitis: a Systematic Review and Meta-analysis

Szerző(k) neve és munkahelye

Anett Rancz, M.D.,1,2 Brigitta Teutsch, M.D.,1,3 Mahmoud Obeidat, M.D.,1 Dániel Sándor Veres, M.D., Ph.D.,4 Bálint Erőss M.D., Ph.D.,1,3,5 Péter Hegyi, M.D., Ph.D., Prof.,1,3,5 Emese Mihály M.D., Ph.D.,2
Affiliations
1 Centre for Translational Medicine, Semmelweis University, Budapest, Hungary;
2 Department of Internal Medicine and Hematology, Semmelweis University, Medical School, Budapest, Hungary;
3 Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary;
4 Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary;
5 Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary;

Bemutatás módja

Poszter

Szekció

Translational Medicine - Posters P

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Introduction: Microscopic colitis (MC) is a chronic inflammatory disease of the large bowel characterized by watery diarrhea, substantially decreasing the patient's quality of life. Scarce data suggest what the risk factors of MC are.
Aims: We aimed to assess MC’s lifestyle and medical risk factors.
Method: Our protocol was prospectively registered with PROSPERO (CRD42022286624). We systematically searched three medical databases from inception to the 18th of December 2021 (Pubmed, Embase, and Cochrane). Cohort, case-control, and cross-sectional studies, reporting on the number of risk factors in MC patients compared to controls with or without a histopathological examination, were included. We used the random-effect model to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs). The risk of bias assessment was made with the aid of the QUIPS tool.
Results: The systematic search yielded 7174 articles, and 43 were eligible for the study. Investigating lifestyle factors, we did not find a significant difference between MC patients with below- and above-high school education. Current smoking was associated with a 1.64 odd (CI:1.06–2.52), while past smoking had a 1.28 odd (CI: 0.91–1.81) of MC compared to both types of controls. Regarding alcohol consumption, we could only do a comparison to controls who weren’t histopathologically examined, and it showed no significant association with MC.
During the medical risk factors examination compared to the overall control group, we found a twofold increased chance of MC diagnosis in the case of the non-steroidal anti-inflammatory drug (NSAID) use (OR =2.07, CI: 1.31–3.27); however, the odds of MC were not significantly increased neither in the case of proton pump inhibitor use (OR =1.59, CI: 0.65–3.90) nor in the case of selective serotonin reuptake inhibitor use (OR =2.10, CI: 0.73–5.98).
Most of the articles were deemed moderate or high risk of bias due to the lack of confounding factors assessment.
Conclusion: Our data demonstrate a 64% increase in the odds of MC with current smoking, while NSAID use is associated with a twofold risk for MC. Further prospective studies with longer follow-ups are needed to further investigate these associations.
Funding: There was no funding.

University and Doctoral School

Semmelweis University, Doctoral School of Pharmaceutical Sciences

Supervisor

Emese Mihály

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

6908

Start

10:30

End

10:35

Authors (legacy)

Anett Rancz, M.D.,1,2 Brigitta Teutsch, M.D.,1,3 Mahmoud Obeidat, M.D.,1 Dániel Sándor Veres, M.D., Ph.D.,4 Bálint Erőss M.D., Ph.D.,1,3,5 Péter Hegyi, M.D., Ph.D., Prof.,1,3,5 Emese Mihály M.D., Ph.D.,2
Affiliations
1 Centre for Translational Medicine, Semmelweis University, Budapest, Hungary;
2 Department of Internal Medicine and Hematology, Semmelweis University, Medical School, Budapest, Hungary;
3 Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary;
4 Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary;
5 Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary;